[ Price : $8.95]
FDA issues a draft guidance detailing expectations for how makers of cuffless, non-invasive blood pressure monitoring devices shou...[ Price : $8.95]
FDA releases the form FDA-483 with 10 observations from an inspection at Japans Sato Pharmaceutical over-the-counter drug manufact...[ Price : $8.95]
FDA issues an early alert warning of a potentially high-risk issue involving certain wound and burn dressings made by Integra Life...[ Price : $8.95]
FDA grants Opna Bio an orphan drug designation for its investigational treatment OPN-2853 (zavabresib) for treating myelofibrosis.[ Price : $8.95]
A United States Pharmacopoeia study finds that protective purchasing following information on drug shortages can adversely affect ...[ Price : $8.95]
FDA commissioner Marty Makary discusses upcoming actions to encourage more prescription-to-over-the-counter drug switches.[ Price : $8.95]
IntraBio reports positive results from a pivotal Phase 3 clinical trial showing that levacetylleucine significantly improved neuro...[ Price : $8.95]
Cogent Biosciences says FDA has agreed to accept the companys planned NDA for cancer drug bezuclastinib under the agencys Real-Tim...